Cicero Diagnostics reaches 10,000-patient milestone with its ReceptivaDx™ Test

ReceptivaDx™ detects inflammation likely caused by endometriosis that is a contributing factor in infertility and recurrent pregnancy loss

HENDERSON, Nev.--(BUSINESS WIRE)--Women’s healthcare company, Cicero Diagnostics Inc., offering ReceptivaDx™ for unexplained infertility, implantation failure and recurrent pregnancy loss, today announced it has reached the 10,000-patient mark from fertility centers using ReceptivaDx™ and its signature BCL6 marker. The milestone signifies substantial test growth since the company’s inception and reflects the role ReceptivaDx™ now plays as a new standard of care in fertility centers helping patients who have experienced IVF failure.

“Today ReceptivaDx™ is used by more than 350 fertility centers around the country and has been introduced in several strategic international markets with more expected,” said Chris Jackson, CEO Cicero Diagnostics. “A driver for the growth has been the steady stream of published data including demonstration of the predictive value of ReceptivaDx™, meaning that an untreated patient who is BCL6-positive will likely experience a failed IVF cycle despite having normal embryos. Conversely, if treated, a patient increases their odds of a live birth 5-fold. Patient volume has nearly doubled every year since 2019 allowing us to expand research and our ability to help patients looking for a pathway to a successful pregnancy.”

Published research efforts helping to drive the momentum behind ReceptivaDx™ include:

• Seminal data from 2016 and 2017 that demonstrate the predictive value of the test in identifying patients likely to fail IVF due to inflammation from endometriosis.
• A 2019 study showing the live birth rate increase when BCL6-positive patients were treated surgically or through GnRh agonists.
• A 2020 study linked here, featuring seven fertility centers and 200 patients using ReceptivaDx™ , all independently reporting similar live birth success replicating the work of the 2019 paper.

Cicero Diagnostics will be attending the American Society for Reproductive Medicine October 17-20^th in Baltimore, MD. The company will share the latest statistics for BCL6 across the spectrum of received samples. They will also be speaking to attending Reproductive Endocrinologists about the benefits of participating in the company’s Shared Experience Program where outcomes data is collated and shared with fertility centers around the world.

About Cicero Diagnostics

Cicero Diagnostics is a medical diagnostic company located in Henderson, NV. ReceptivaDx™ is the company’s signature test panel around unexplained infertility. Cicero Diagnostics is the exclusive licensed provider of the BCL6 test for the detection of uterine lining dysfunction commonly associated with endometriosis. Cicero works with fertility centers across the U.S. and in 16 other countries. Cicero Diagnostics continues to expand their offering globally and is investing in continued research in the field. Cicero’s diagnostics is currently being used at more than 350 fertility centers across the US. Cicero is proud to partner with providers working to help solve female infertility issues.